MY202395A - Gremlin-1 crystal structure and inhibitory antibody - Google Patents

Gremlin-1 crystal structure and inhibitory antibody

Info

Publication number
MY202395A
MY202395A MYPI2019003411A MYPI2019003411A MY202395A MY 202395 A MY202395 A MY 202395A MY PI2019003411 A MYPI2019003411 A MY PI2019003411A MY PI2019003411 A MYPI2019003411 A MY PI2019003411A MY 202395 A MY202395 A MY 202395A
Authority
MY
Malaysia
Prior art keywords
gremlin
crystal structure
inhibitory antibody
antibody
human
Prior art date
Application number
MYPI2019003411A
Other languages
English (en)
Inventor
Neesha Dedi
Breda Twomey
Michael John Wright
David James Mcmillan
Gareth Charles Glyndwr Davies
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MY202395A publication Critical patent/MY202395A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
MYPI2019003411A 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody MY202395A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1621635.0A GB201621635D0 (en) 2016-12-19 2016-12-19 Crystal structure
PCT/EP2017/083650 WO2018115017A2 (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody

Publications (1)

Publication Number Publication Date
MY202395A true MY202395A (en) 2024-04-25

Family

ID=58284547

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019003411A MY202395A (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody

Country Status (27)

Country Link
US (3) US10947304B2 (enExample)
EP (1) EP3555129A2 (enExample)
JP (1) JP7097364B2 (enExample)
KR (1) KR102557216B1 (enExample)
CN (1) CN110099924B (enExample)
AR (1) AR110394A1 (enExample)
AU (1) AU2017384471B2 (enExample)
BR (1) BR112019010903A2 (enExample)
CA (1) CA3045742A1 (enExample)
CL (1) CL2019001715A1 (enExample)
CO (1) CO2019006073A2 (enExample)
EA (1) EA201991511A1 (enExample)
EC (1) ECSP19051912A (enExample)
GB (1) GB201621635D0 (enExample)
IL (1) IL267287A (enExample)
MA (1) MA47669A (enExample)
MX (1) MX2019006630A (enExample)
MY (1) MY202395A (enExample)
PE (1) PE20191542A1 (enExample)
PH (1) PH12019501319A1 (enExample)
RU (1) RU2769285C2 (enExample)
TN (1) TN2019000188A1 (enExample)
TW (1) TWI787223B (enExample)
UA (1) UA126025C2 (enExample)
UY (1) UY37528A (enExample)
WO (1) WO2018115017A2 (enExample)
ZA (1) ZA201903810B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) * 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
JP7565219B2 (ja) * 2018-06-18 2024-10-10 ユーシービー バイオファルマ エスアールエル がんを予防及び治療するためのｇｒｅｍｌｉｎ－１アンタゴニスト
US20240294622A1 (en) * 2021-01-18 2024-09-05 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
TW202300527A (zh) * 2021-03-11 2023-01-01 上海交通大學 使用ｇｒｅｍ１拮抗劑治療疾病的方法
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
EP4511395A1 (en) * 2022-04-20 2025-02-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
UY40783A (es) 2023-06-12 2024-12-31 Amgen Inc Proteínas de unión a agonistas del receptor beta de linfotoxina

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU2002243495A1 (en) 2001-01-12 2002-07-24 University Of Medicine And Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
DK1644412T4 (en) 2003-07-01 2018-11-12 Ucb Biopharma Sprl MODIFIED ANTIBODY-FAB FRAGMENTS
WO2005023993A2 (en) 2003-09-09 2005-03-17 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2007124486A2 (en) 2006-04-21 2007-11-01 Childrens Hospital Los Angeles Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
JP6339063B2 (ja) 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
MX369574B (es) 2013-03-14 2019-11-13 Regeneron Pharma Anticuerpos humanos contra grem1.
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
JP7565219B2 (ja) 2018-06-18 2024-10-10 ユーシービー バイオファルマ エスアールエル がんを予防及び治療するためのｇｒｅｍｌｉｎ－１アンタゴニスト

Also Published As

Publication number Publication date
JP2020511946A (ja) 2020-04-23
KR20190093658A (ko) 2019-08-09
RU2019122648A3 (enExample) 2021-07-02
UA126025C2 (uk) 2022-08-03
TW201837052A (zh) 2018-10-16
US10947304B2 (en) 2021-03-16
TWI787223B (zh) 2022-12-21
NZ754018A (en) 2024-07-26
IL267287A (en) 2019-08-29
US20240076365A1 (en) 2024-03-07
US20190330323A1 (en) 2019-10-31
PE20191542A1 (es) 2019-10-23
EP3555129A2 (en) 2019-10-23
WO2018115017A2 (en) 2018-06-28
CA3045742A1 (en) 2018-06-28
EA201991511A1 (ru) 2019-11-29
US11807680B2 (en) 2023-11-07
RU2019122648A (ru) 2021-01-19
BR112019010903A2 (pt) 2019-10-01
AU2017384471A1 (en) 2019-06-13
AR110394A1 (es) 2019-03-27
RU2769285C2 (ru) 2022-03-30
CL2019001715A1 (es) 2019-11-29
TN2019000188A1 (en) 2020-10-05
AU2017384471B2 (en) 2024-08-22
PH12019501319A1 (en) 2020-03-02
MX2019006630A (es) 2019-08-21
GB201621635D0 (en) 2017-02-01
ECSP19051912A (es) 2019-07-31
US20210163586A1 (en) 2021-06-03
KR102557216B1 (ko) 2023-07-18
US12473355B2 (en) 2025-11-18
CN110099924A (zh) 2019-08-06
ZA201903810B (en) 2020-12-23
WO2018115017A3 (en) 2019-02-07
CO2019006073A2 (es) 2019-06-19
CN110099924B (zh) 2023-11-10
MA47669A (fr) 2020-01-08
JP7097364B2 (ja) 2022-07-07
UY37528A (es) 2018-07-31

Similar Documents

Publication Publication Date Title
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
MX2021004270A (es) Anticuerpos estabilizadores de trem2.
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201692458A1 (ru) Анти-gitr антитела и способы их применения
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
PH12018502502A1 (en) Anti-gitr antibodies and uses thereof
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
GEP20207166B (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EP4406554A3 (en) Anti-cd3 antibody formulations
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
WO2019136300A3 (en) Anti-mct1 antibodies and uses thereof
PH12019501108A1 (en) Anti-gitr anti-binding protein and methods of use thereof
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
MY194084A (en) Interferon beta antibodies and uses thereof
AU2018279184A1 (en) Anti-TrkB antibodies
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
MX2021007846A (es) Proteinas que se unen a anti-pd-l1 y metodos de uso de las mismas.
DOP2012000266A (es) PROTEÍNAS QUE SE UNEN AL TNF-a